Stock info Vertex Pharma | Filter  Basic-Info

Vertex Pharma

The past year was a profitable year for the Vertex Pharma investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Vertex Pharma. The stock lost around 36 percent. Over the period from December 2011 till December 2016 the stock rose on average 131 percent. Vertex Pharma's revenues between 2011 and 2015 were very fluctuating and moved between 17,46 million dollars and 72,59 million dollars. Vertex Pharma's net incomes between 2011 and 2015 were very volatile through the time and moved between -3,15 million dollars and -28,54 million dollars.

Vertex Pharma is active in the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The American company didn't pay out any dividends (in the past 5 years).

Vertex Pharma' balance mostly consists of equity

Last year the balance sheet of the American company was worth 86,69 million dollars. Of the total balance sheet 55 million dollars (63,44 percent) was financed by debt. As per the end of 2015 Vertex Pharma's price/earnings-ratio equaled 0. So investors paid for 1 stock 0 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 6,38 billion dollars. At the end of 2015 the American company had around 52,38 million stocks listed.

All Vertex Pharma's financial reports are available here. More information about Vertex Pharma can be found it's website. .